Join
Live feed
·
PRReleasevia Quantisnow
Savara Inc. logo

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

ByQuantisnow·Wall Street's wire, on your screen.
SVRA· Savara Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SVRA (Savara Inc.) and more on Quantisnow.